Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

Abstract

Since H51Y and R263K may define a unique resistance pathway to dolutegravir, our results are consistent with the absence of resistance mutations in antiretroviral drug-naive patients treated with this drug.